Has Kristina Duffin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $88,733 in general payments to Kristina Duffin, MD across 237 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kristina Duffin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kristina Duffin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kristina Duffin, MD

Dermatology · Salt Lake City, UTNPI 1659397040

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $68,058 of the $88,733 with a category attached, or 76.7%. It is spread thinly across 21 manufacturers, the largest accounting for just 14.9%. Reporting peaked in 2021 at $23,616 and has fallen 90.7% since, to $2,204 in 2025. Among dermatology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$88,733in general payments, 2019–2025

Across 237 payments — averaging $374.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$13K
AbbVie$12K
Boehringer Ingelheim$12K
Johnson & Johnson$12K
Amgen$8K
Boehringer Ingelheim International GmbH$7K
plus $24K from 15 others

$1,110,643in research payments, 2019–2025

Across 142 payments — averaging $7821.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$477K
UCB SA$218K
Boehringer Ingelheim$133K
Amgen$105K
Janssen Research & Development, LLC$64K
AbbVie$53K
plus $62K from 7 others

What the payments were for

Consulting fees$68,05877%
Speaking & faculty fees$8,0209%
Grants$2,0432%
Travel & lodging$6,4787%
Food & beverage$3,9754%
Education$1600%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	20	$13,247
AbbVie	41	$12,462
Boehringer Ingelheim	7	$11,994
Johnson & Johnson	28	$11,889
Amgen	33	$8,420
Boehringer Ingelheim International GmbH	14	$6,572
E.r. Squibb & Sons, L.L.C.	16	$5,853
LEO Pharma AS	16	$4,229
Bristol Myers Squibb	17	$3,475
UCB SA	14	$2,582
Sanofi	1	$2,043
Boehringer Ingelheim Pharma GmbH & Co.kg	6	$1,907
Eli Lilly	1	$1,400
Lilly USA, LLC	5	$990
Janssen Global Services, LLC	2	$635
UCB, Inc.	9	$525
Arcutis Biotherapeutics, Inc.	3	$270
Janssen Scientific Affairs, LLC	1	$147
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$42
Sun Pharmaceutical Industries Inc.	1	$27
LEO Pharma Inc.	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$12,264
SPEVIGO$11,396
Enbrel$7,372
Skyrizi$4,275
COSENTYX$2,471
TALTZ$800
Sotyktu$149
Otezla$145

How this compares

$88,733 in reported general payments places this provider in the 95th percentile of 163 dermatology providers in Utah.

See all dermatology providers in Utah →

Medicare billing

Part B allowed, 2024

$14,979

Medicare patients

Services billed

212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	22	$459,165
Taltz AutoinjectorIxekizumab	20	$133,614
Humira PenAdalimumab	12	$96,313
Clobetasol Propionate	33	$1,232
MethotrexateMethotrexate Sodium	24	$357

Paid to pharmacies, not to this prescriber.

Other dermatology in Salt Lake City

Gerald KruegerSalt Lake City$156K
Mark TaylorSalt Lake City$58K
Stephanie ZoneSalt Lake City$22K
Lauren MadiganSalt Lake City$21K
Elena HadjicharalambousSalt Lake City$9K
Grace BrummerSalt Lake City$4K
Megan ProutySalt Lake City$3K
Michael SotiriouSalt Lake City$3K
Dev SahniSalt Lake City$3K
Margaret CocksSalt Lake City$2K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →